health
Experimental Pill Offers New Hope for Deadly Pancreatic Cancer
Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients.
TL;DR
- A new experimental drug, daraxonrasib, shows significant promise for advanced pancreatic cancer.
- The drug nearly doubled median survival time, from 6.7 months to 13.2 months, compared to traditional chemotherapy.
- Daraxonrasib targets a mutated protein that fuels tumor growth in over 90% of pancreatic cancer cases.
- Patients taking the pill experienced fewer severe side effects and reported a better quality of life.
- The drug is considered a potential new standard of care and is undergoing expedited FDA review.
- Pancreatic cancer remains one of the deadliest cancers, with a low overall survival rate.